Triple Negative Breast Cancer Clinical Trials in New York, New York

18 studies are recruiting for triple negative breast cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

   This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and d…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York, New York

   Locations

   311 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06393374 on ClinicalTrials.gov

2. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Longone Health, New York, New York

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Memorial Sloan Kettering, New York, New York

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

4. A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

   Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06246968 on ClinicalTrials.gov

5. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

   The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Canter, New York, New York

   Locations

   372 in total

   Run by

   Gilead Sciences

   See if you can join NCT05633654 on ClinicalTrials.gov

6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

7. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132, New York, New York

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

8. A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

   The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.

   Stage

   Phase 2

   Ages

   70 and older

   Site

   Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07768436 on ClinicalTrials.gov

9. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

   The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York

   Locations

   13 in total

   Run by

   Pfizer

   See if you can join NCT07318805 on ClinicalTrials.gov

10. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    New York University Langone Health, New York, New York

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

11. A Study of LY4175408 in Participants With Advanced Cancer

    The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University, New York, New York

    Locations

    27 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07046923 on ClinicalTrials.gov

12. A Study of Tetrathiomolybdate (TM) Plus Capecitabine

    There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer. In the ph…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    NYU Langone perimutter Cancer Center, New York, New York

    Locations

    3 in total

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT06134375 on ClinicalTrials.gov

13. A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

    The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    6 in total

    Run by

    Mabwell (Shanghai) Bioscience Co., Ltd.

    See if you can join NCT06908928 on ClinicalTrials.gov

14. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    12 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT03808337 on ClinicalTrials.gov

15. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

    The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04683679 on ClinicalTrials.gov

16. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center Head Neck Services, New York, New York

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

17. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    14 in total

    Run by

    Volastra Therapeutics, Inc.

    See if you can join NCT05902988 on ClinicalTrials.gov

18. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov